BioNTech
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and chief executive officer of BioNTech.
Pharma companies add new members to executive ranks and boards of directors.
Companies from across the globe provide updates on their business and product pipelines.
This makes it one of the biggest single private funding rounds for a biotechnology company in European history.
JOBS
IN THE PRESS